Joerg Berghausen
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Chemical Synthesis and Analysis, Computational Drug Discovery Methods, Analytical Chemistry and Chromatography, Crystallization and Solubility Studies
Most-Cited Works
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors(2015)203 cited
- → Polymorphism - integrated approach from high-throughput screening to crystallization optimization(2003)72 cited
- → Accelerated Formulation Development for Nanomilled Active Pharmaceutical Ingredients Using a Screening Approach(2010)54 cited
- → Modulation of Oral Bioavailability and Metabolism for Closely Related Cyclic Hexapeptides(2017)27 cited
- → Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey(2022)25 cited
- → Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach(2020)22 cited
- → Simulated rat intestinal fluid improves oral exposure prediction for poorly soluble compounds over a wide dose range(2016)12 cited
- → Pyridyl-Ala Modified Cyclic Hexapeptides: In-Vitro and In-Vivo Profiling for Oral Bioavailability(2019)5 cited
- → Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial(2014)4 cited